Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1951 to 1965 of 8906 results

  1. Sonesitatug vedotin for previously treated metastatic claudin 18.2-positive gastric or gastro-oesophageal junction adenocarcinomar [ID6669]

    Awaiting development Reference number: GID-TA11879 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Trilaciclib for preventing myelosuppression caused by chemotherapy for extensive-stage small-cell lung cancer [ID6651]

    Awaiting development Reference number: GID-TA11863 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Heart valve disease presenting in adults: investigation and management - transcatheter aortic valve implantation (TAVI) to treat aortic stenosis (update)

    In development Reference number: GID-NG10457 Expected publication date: TBC

    NICE guideline
    In development

  4. Concizumab for treating severe haemophilia A or moderate to severe haemophilia B in people 12 years and over without inhibitors [ID5099]

    Awaiting development Reference number: GID-TA10972 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Upadacitinib for treating moderate to severe hidradenitis suppurativa in people 12 years and over [ID6666]

    Awaiting development Reference number: GID-TA11825 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Elranatamab for treating relapsed or refractory multiple myeloma after 2 treatments [ID6464]

    Awaiting development Reference number: GID-TA11661 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Surovatamig for treating relapsed or refractory B-cell acute lymphoblastic leukaemia after 2 or more lines of treatment in people 12 years and over [ID6630]

    Awaiting development Reference number: GID-TA11837 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Surovatamig for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more lines of treatment [ID6631]

    Awaiting development Reference number: GID-TA11849 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Mosunetuzumab with lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6655]

    Awaiting development Reference number: GID-TA11867 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Pirtobrutinib with venetoclax and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6566]

    Awaiting development Reference number: GID-TA11748 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Zongertinib for treating HER2-mutated unresectable or metastatic non-small-cell lung cancer [ID6573]

    Awaiting development Reference number: GID-TA11755 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Lisocabtagene maraleucel for treating relapsed or refractory low-grade B-cell follicular lymphoma after 1 or more treatments [ID6564]

    Awaiting development Reference number: GID-TA11754 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Pembrolizumab for adjuvant treatment of triple-negative breast cancer after neoadjuvant chemotherapy [ID6546]

    Awaiting development Reference number: GID-TA11724 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Trastuzumab deruxtecan with or without pertuzumab for untreated HER2-positive metastatic breast cancer [ID6548]

    Awaiting development Reference number: GID-TA11723 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Tovorafenib for treating relapsed or refractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation in people 6 months and over ID6557

    In development Reference number: GID-TA11693 Expected publication date: TBC

    Technology appraisal guidance
    In development